Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Macroencapsulation Device with Anti-inflammatory Membrane Modification Enhances Long-Term Viability and Function of Transplanted β Cells.
ACS Appl Mater Interfaces
December 2024
Department of Bioengineering and Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.
Treating type 1 diabetes (T1D) through β-cell macroencapsulation is a promising long-term solution, but it faces challenges such as immune-mediated fibrosis on the capsule surface, which impairs cell functionality and compromises longevity and effectiveness. This study presents an approach for including an anti-inflammatory molecule on the macroencapsulation device (MED) using initiated chemical vapor deposition for the surface modification of poly(tetrafluoroethylene) (PTFE) membranes. The surface-modified MEDs significantly reduced fibrosis, improved β-cell viability and functionality, and promoted M2 macrophage polarization, which is associated with anti-inflammatory effects.
View Article and Find Full Text PDFSustained release of nano-encapsulated glimepiride drug with chitosan nanoparticles: A novel approach to control type 2 diabetes in streptozotocin-induced Wistar albino rats.
Int J Biol Macromol
December 2024
Unit of Nanotechnology and Bioactive Natural Products, Post Graduate and Research Department of Zoology, C. Abdul Hakeem College (Autonomous), Melvisharam - 632 509, Ranipet District (Affiliated to Thiruvalluvar University, Vellore), Tamil Nadu, India.
The objective of the present study was to encapsulate the effective antidiabetic glimepiride (GLM) drug with biodegradable chitosan nanoparticles (CS NPs) in order to reduce the risk of side effects, regulate and improve alternatives to therapy for people with type 2 Diabetes mellitus. The characterizations of the encapsulated EGLM-CS NPs were published in a previous paper. In continuation of the past study, here we report the in vitro and in vivo activities of EGLM-CS NPs in streptozotocin-induced diabetes Wistar albino rats orally treated for 28 days.
View Article and Find Full Text PDFAlginate-Poly[2-(methacryloyloxy)ethyl]trimethylammonium Chloride (PMETAC) Immunoisolating Capsules Prolong the Viability of Pancreatic Islets In Vivo.
Biomedicines
November 2024
Federal State Budgetary Institution of Higher Education "Privolzhsky Research Medical University" of the Ministry of Health of Russia, 603005 Nizhny Novgorod, Russia.
Background/objectives: This study focuses on the development and evaluation of novel alginate-poly[2-(methacryloyloxy)ethyl]trimethylammonium chloride (PMETAC) microcapsules for encapsulating pancreatic islets to address insulin deficiency in diabetes.
Methods: In previous research, we fabricated and characterized PMETAC microcapsules, evaluating their stability and permeability in vitro. This study further probes the capsules in vivo, focusing on the functional activity of the encapsulated islets post-transplantation, their viability extension, and the assessment of the immunoprotective, antifibrotic properties, and biostability of the capsules.
A 3D-printed microdevice encapsulates vascularized islets composed of iPSC-derived β-like cells and microvascular fragments for type 1 diabetes treatment.
Biomaterials
April 2025
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address:
Transplantation of insulin-secreting cells provides a promising method for re-establishing the autonomous blood glucose control ability of type 1 diabetes (T1D) patients, but the low survival of the transplanted cells hinder the therapeutic efficacy. In this study, we 3D-printed an encapsulation system containing β-like cells and microvascular fragments (MVF), to create a retrivable microdevice with vascularized islets in vivo for T1D therapy. The functional β-like cells were differentiated from the urine epithelial cell-derived induced pluripotent stem cells (UiPSCs).
View Article and Find Full Text PDFChallenges in Beta Cell Replacement for Type 1 Diabetes.
Horm Res Paediatr
October 2024
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Background: Type 1 diabetes (T1D), a disease characterized by immune-mediated destruction of beta-cells, presents a significant global health challenge. Achieving therapeutic goals such as prevention of immune destruction, preservation of beta-cell mass, and automated insulin delivery remains complex due to the disease's heterogeneity.
Summary: This review explores the advancements and challenges in beta-cell replacement therapies, including pancreas and islet cell transplantation, stem cell-derived β-cell generation, and biotechnological innovations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!